Key result
LMCA-PCI reduces NT-proBNP by ~33%, with greater declines predicting lower major cardiovascular events and mortality.
Why the study?
Whether PCI improves event-free survival over optimal medical therapy alone in LMCA disease remains controversial, and previous trials included few LMCA-PCIs. This study evaluated the clinical benefits of LMCA-PCI using NT-proBNP as a prognostic marker.
Does NT-proBNP dynamics predict MACE and all-cause mortality in patients undergoing left main coronary artery percutaneous coronary intervention?
Cohort (n=240)
No
Does NT-proBNP dynamics predict MACE and all-cause mortality in patients undergoing left main coronary artery percutaneous coronary intervention?
In patients undergoing left main PCI, a reduction in NT-proBNP post-intervention is associated with a lower risk of MACE and all-cause mortality, highlighting its utility for risk stratification.
Answers are grounded in this paper and cite their sources.
NT-proBNP reduction after LMCA-PCI was associated with lower MACE and mortality; hypothesis-generating for prospective validation in risk stratification.
Background Indications for percutaneous coronary intervention (PCI) in the treatment of coronary artery disease (CAD) have expanded significantly in recent years due to technical improvements, especially in complex cases including left main coronary artery (LMCA) stenosis. Whether PCI improves event-free survival compared to optimal medical therapy (OMT) alone remains, nevertheless, controversially discussed in current literature. The recently published REVIVED-BCIS2 trial [1] showed no survival benefit of PCI in addition to OMT in patients with severe ischemic reduced left ventricular function - however, only a limited number of LMCA-PCIs were included. Purpose Considering the critical role of LMCA in left ventricular perfusion and its association with increased mortality when diseased, this study aims to evaluate the clinical benefits of LMCA-PCI using N-terminal prohormone of brain natriuretic peptide (NT-proBNP) as a prognostic marker and indicator of heart failure. Methods A total of 240 patients over 18 years of age who underwent LMCA-PCI at our university hospital between 2010 and 2021 were included in this study. Baseline NT-proBNP levels at the time of LMCA-PCI and follow-up values at a median of 5.9 months post-intervention were collected for each patient. The primary study endpoint was MACE (composite of cardiovascular death, non-fatal myocardial infarction, ischemic stroke, and hospitalization for heart failure). All-cause mortality was defined as secondary endpoint. Results The study cohort consisted predominantly of male patients (76.3%) with a median age of 70.5 years. Baseline NT-proBNP was significantly associated with long-term MACE (adj. HR per 1 SD 1.35 [1.08-1.70]; p = 0.009) and all-cause mortality (adj. HR per 1 SD 1.81 [1.36-2.41]; p < 0.001), even after adjustment for age, sex, BMI and urgency of intervention (Figure 1). Analysis of NT-proBNP dynamics, represented by NT-proBNP quotient (calculated as follow up NT-proBNP divided by baseline NT-proBNP), revealed a significant median reduction of 33% in NT-proBNP levels post-intervention (paired Wilcoxon test; p < 0.001). Notably, patients with highest baseline NT-proBNP values (3rd tertile) exhibited the most pronounced decrease of 55% (paired Wilcoxon test; p < 0.001; Figure 2). Interestingly, NT-proBNP quotient emerged as a robust predictor of MACE (adj. HR per 1 SD 1.39 [1.15-1.69]; p < 0.001) and all-cause mortality (adj. HR per 1 SD 1.99 [1.55-2.56]; p < 0.001), with a greater reduction correlating with a lower event risk. Conclusions Our findings highlight the prognostic value of NT-proBNP in LMCA-PCI patients for predicting adverse clinical events. The observed post-intervention decrease in NT-proBNP suggests a favourable effect of LMCA-PCI. The dynamic change in NT-proBNP serves as a robust predictor for adverse outcomes, emphasizing its potential utility in risk stratification and patient management following LMCA-PCI.
No takes yet. Share an insight, caveat, or question.
Steinacher et al. (2025) conducted a cohort in Left main coronary artery (LMCA) stenosis (n=240). Baseline NT-proBNP and NT-proBNP dynamics was evaluated on MACE (composite of cardiovascular death, non-fatal myocardial infarction, ischemic stroke, and hospitalization for heart failure) (HR 1.35, 95% CI 1.08-1.70, p=0.009). Baseline NT-proBNP levels were associated with long-term major cardiovascular events following left main coronary artery PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: